Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 3-Year Revenue Growth Rate is 22.30% as of Jun. 2026, which is 41% above its 10-year median of 15.85. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.45 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 755 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 86.23% on this metric.
During the past 12 months, Xvivo Perfusion AB's average Revenue per Share Growth Rate was 9.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 22.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 34.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Xvivo Perfusion AB was 44.80% per year. The lowest was 4.40% per year. And the median was 15.85% per year.
Xvivo Perfusion AB (OTCPK:XVIPF) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Xvivo Perfusion AB 3-Year Revenue Growth Rate Related Terms
XVIPF vs ABT, SYK, MDT: 3-Year Revenue Growth Rate Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 3-Year Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 3-Year Revenue Growth Rate falls into.
Xvivo Perfusion AB 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 22.30% mean?
Xvivo Perfusion AB (XVIPF) has a 3-Year Revenue Growth Rate of 22.30% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Xvivo Perfusion AB and its competitors. This is 41% above median its historical median of 15.85. Over the past decade, Xvivo Perfusion AB's 3-Year Revenue Growth Rate has ranged from 4.40 to 44.80. According to the industry distribution chart, Xvivo Perfusion AB ranks #104 out of 755 companies in the Medical Devices & Instruments industry, placing it in the top 13.8%.
Is Xvivo Perfusion AB's 3-Year Revenue Growth Rate too high?
Xvivo Perfusion AB's current 3-Year Revenue Growth Rate of 22.30% is 41% above median its 10-year median of 15.85. Over the past 10 years, this metric has ranged from a low of 4.40 to a high of 44.80. The Medical Devices & Instruments industry median 3-Year Revenue Growth Rate is 3.80. Xvivo Perfusion AB's value of 22.30% is 486.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #104 out of 755 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 3-Year Revenue Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #104 out of 755 companies for 3-Year Revenue Growth Rate. This places Xvivo Perfusion AB in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 3.80. Xvivo Perfusion AB's value of 22.30% is 486.8% above this benchmark. Historically, Xvivo Perfusion AB's own 3-Year Revenue Growth Rate has ranged from 4.40 to 44.80 over the past decade. While the company's 10-year median is 15.85 vs. the industry median of 3.80, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Revenue Growth Rate among Medical Devices & Instruments companies is 3.80, based on 755 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current 3-Year Revenue Growth Rate of 22.30% is 486.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Revenue Growth Rate is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current 3-Year Revenue Growth Rate is 22.30%, which is 41% above median its own 10-year median of 15.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.45, compared to a current price of $24.50 — trading 44.9% below its estimated fair value. The current 3-Year Revenue Growth Rate is 22.30%, which is 41% above median its 10-year median of 15.85 and 486.8% above the Medical Devices & Instruments industry median of 3.80. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 3-Year Revenue Growth Rate is 22.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.9% below its estimated GF Value™ of $44.45.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
3-Year Revenue Growth Rate: 22.30% (41% above median its 10-year median of 15.85)
GF Value™: $44.45 vs. price of $24.50 (44.9% below fair value)
Industry Position: 486.8% above the Medical Devices & Instruments median (#104 of 755)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
